<DOC>
	<DOCNO>NCT00040183</DOCNO>
	<brief_summary>The purpose study determine OSI-774 improve overall survival combine standard dose chemotherapy drug gemcitabine , individual pancreatic cancer .</brief_summary>
	<brief_title>OSI-774 ( Tarceva ) Plus Gemcitabine Patients With Locally Advanced , Unresectable Metastatic Pancreatic Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis adenocarcinoma pancreas ; cancer unresectable , locally advanced metastatic . Must evidence disease ( clinical radiological ) . Male female , 18 year old . Patients may receive prior radiation treatment management local disease provide disease progression document . All toxicity resolve , last fraction radiation treatment complete least 4 week prior randomization . Patients may receive prior chemotherapy , 5FU ( +/ folic acid ) gemcitabine give concurrently radiation treatment 'radiosensitiser . '</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Tarceva , EGFR , erlotinib , OSI-774</keyword>
</DOC>